Search

Relay Therapeutics Inc

Gesloten

SectorGezondheidszorg

18.1 0.17

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

18.02

Max

18.2

Belangrijke statistieken

By Trading Economics

Inkomsten

2M

-82M

EPS

-0.37

Winstmarge

-23,916.286

Werknemers

218

EBITDA

1.9M

-81M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+60.31% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

719M

4.5B

Vorige openingsprijs

17.93

Vorige sluitingsprijs

18.1

Relay Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 nov 2026, 21:07 UTC

Relay Therapeutics, Inc. shares are rising, supported by gains in the Biotechnology sub-sector, despite earlier pulling back from a session high amid volatility.

12 nov 2026, 22:11 UTC

Relay Therapeutics, Inc. finished lower in after-market trading, continuing a trend of declines and remaining below its 20-day moving average.

10 nov 2026, 21:07 UTC

Relay Therapeutics, Inc. shares declined sharply, reversing from an early peak and finishing near session lows, reflecting a weaker performance since Monday's close.

9 nov 2026, 21:03 UTC

Relay Therapeutics, Inc. shares are advancing sharply, trading with unusually high volume and well above its 20-day moving average.

6 nov 2026, 21:02 UTC

News

Jones Trading analyst Boris Peaker raised the price target on Relay Therapeutics to $31.00 from $20.00 while maintaining a Buy rating.

5 nov 2026, 21:04 UTC

Relay Therapeutics, Inc. shares are declining amid a broader market downturn, remaining under pressure and trading near the lower end of their one-month range.

4 nov 2026, 22:02 UTC

News

Relay Therapeutics reported a net loss of $81.7 million, or $0.37 per share, for Q3 2026, better than the expected $0.40 loss.

3 nov 2026, 20:46 UTC

Relay Therapeutics, Inc. is trading higher on Tuesday after reaching a peak earlier in the session, though it remains below its 20-day moving average.

2 nov 2026, 21:04 UTC

Shares of Relay Therapeutics, Inc. fell sharply, reversing recent upward momentum amid a broader decline in the market.

30 okt 2026, 20:03 UTC

Relay Therapeutics, Inc. shares fell sharply after briefly rising earlier in the session.

29 okt 2026, 20:07 UTC

Shares of Relay Therapeutics, Inc. declined, pulling back from an earlier session high, as part of a broader market trend closing lower.

28 okt 2026, 23:36 UTC

News

Relay Therapeutics will report its Q3 2026 financial results on November 4, 2026, after the market close, amid ongoing development of zovegalisib.

27 okt 2026, 20:31 UTC

Relay Therapeutics, Inc. is seeing modest gains in after-market trading, rising from a low shortly after the market closed and trading above its 20-day moving average.

26 okt 2026, 19:46 UTC

Relay Therapeutics Inc shares are declining, continuing a downward trend observed over the last three sessions, despite a brief peak earlier in the session.

23 okt 2026, 20:07 UTC

Relay Therapeutics Inc shares are declining amid a broader market downturn, despite an earlier rebound from a session low.

22 okt 2026, 19:56 UTC

Social Media

Relay Therapeutics Inc shares are modestly lower, having retraced from an early gain and currently positioned around the midpoint of its one-month trading range.

21 okt 2026, 19:36 UTC

Relay Therapeutics Inc shares are declining, pulling back from an earlier peak, and are modestly lower since Tuesday's close amid session volatility.

20 okt 2026, 20:01 UTC

Relay Therapeutics Inc shares are advancing sharply, continuing an upward trend with a notable increase since Monday's close, reaching a peak before the close.

19 okt 2026, 19:46 UTC

Relay Therapeutics Inc shares are sharply higher.

16 okt 2026, 20:02 UTC

Relay Therapeutics Inc shares are declining, reversing a trend of higher daily closes observed in recent sessions, reflecting a shift in momentum.

15 okt 2026, 19:46 UTC

Relay Therapeutics Inc is trading higher, having reached a peak return during Thursday's session.

14 okt 2026, 20:07 UTC

Relay Therapeutics Inc shares are declining, positioned near the lower end of their one-month range and below the 20-day moving average.

13 okt 2026, 20:07 UTC

Relay Therapeutics Inc shares are declining, following significant volatility and a drop to their lowest point mid-session, trading well below the 20-day moving average.

12 okt 2026, 22:02 UTC

Relay Therapeutics Inc shares are trading modestly lower in after-market hours, continuing a decline amid broader weakness in the biotechnology sector.

9 okt 2026, 20:06 UTC

Relay Therapeutics Inc shares are advancing, continuing a recovery trend after prior declines, despite earlier pulling back from a notable peak in today's session.

8 okt 2026, 23:01 UTC

Relay Therapeutics Inc shares are sharply lower in after-market trading, continuing a trend of declines following four consecutive lower daily closes.

7 okt 2026, 19:35 UTC

Relay Therapeutics Inc shares fell sharply, reaching their lowest point around mid-day, despite a brief rebound earlier in the session.

6 okt 2026, 20:00 UTC

Relay Therapeutics Inc shares fell sharply, breaking a trend of higher daily closes amid unusually high volume and a broader downturn in the biotechnology sector.

5 okt 2026, 19:16 UTC

Relay Therapeutics Inc is gaining, recovering from an earlier low and continuing an upward trend after three consecutive sessions of positive performance.

2 okt 2026, 21:01 UTC

Relay Therapeutics Inc declined during after-market hours, moving lower from Friday's close after initially starting with a slight gain.

Peer Vergelijking

Prijswijziging

Relay Therapeutics Inc Prognose

Koersdoel

By TipRanks

60.31% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29 USD  60.31%

Hoogste 31 USD

Laagste 26 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Relay Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat